PPD CorEvitas Precision Medicine
Advance the development of novel interventions
Development of new interventions has traditionally been a one-size-fits-all approach, where research is based on a homogenous participant pool and approvals and use are based on the average patient in a specific disease area. The 2015 launch of the Precision Medicine Initiative gave rise to a bolder, more personalized approach that identifies and considers distinct differences and complexities, leading to the growth of interventions that are precisely targeted to individuals.
A significant characteristic of precision medicine research is the use of human biospecimens to generate data that provide insights for biomarker discovery, translation and validation, ultimately leading to disease diagnosis and the development of treatments. Available biospecimens, therefore, are critical for the advancement of personalized medicine.
Harness the innovation of personalized medicine with access to human biospecimens linked to our deep, rich longitudinal PPD™ CorEvitas™ Registry data.. These capabilities enable you to advance the molecular understanding of a specific disease and put you on the path to developing novel therapeutics, diagnostics and prognostic tools.
Biospecimens at your fingertips
Gain the information you need to develop precision medicine with precise biospecimens. A comprehensive and rigorous biospecimen collection process ensures the right analysis of the right samples, including DNA, RNA, serum and plasma. Highly characterized and annotated to provide the level of detail you need to advance your research, these samples are available on a per-sample basis and can be obtained for proprietary analysis or through strategic laboratory partnerships. Meet scientific objectives with biospecimens that can be:
- Customized and deployed quickly
- Flexible and cost-effective, leveraging our clinical research expertise, active protocols and extensive site and patient network
- Used to support both pre- and post-marketing objectives and regulatory commitments
Benefits of biospecimen use in research
Natural history studies
The increasing development of cell and gene therapies and precision medicine has led to novel needs in terms of real-world evidence generation. A key area highlighted in the U.S. Food and Drug Administration’s guidance on rare diseases is the recommendation to use natural history studies to better characterize and delineate target patient populations.. These epidemiological studies focus on describing the frequency, features and evolution of a disease by collecting real-world data from patients suffering from the disease in question. The inclusion of genetic testing to describe specific genetic profiles as part of the features of the patient population, or as a screening criterion to identify the target population, is increasing.